All In MedTech

Device Trial Radar · NCT02232659

SynCardia 70cc TAH-t for Destination Therapy (DT)

SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT)

Last checked: Nov 20, 2026Latest source record: Mar 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

38

Planned (sponsor's estimate)

Start

Feb 2016

Primary completion

Dec 2021

Study completion May 2022

Sponsor

Lead sponsor
SynCardia Systems. LLCNot on our public-company list
Sponsor type
Industry
First posted
Sep 5, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The SynCardia 70cc temporary Total Artificial Heart (TAH-t) is approved by the U.S. Food and Drug Administration (FDA) for use as a bridge to transplant for patients at risk of imminent (about to happen) death from irreversible biventricular heart failure. The purpose of this research study is to evaluate whether the TAH-t can support patients with life-threatening irreversible biventricular heart failure who are not eligible for transplantation. The TAH-t, when used for patients who are not eligible for transplant, is considered to be an investigational (not approved by FDA) use. This use is called destination therapy (DT). Nineteen (19) patients with life-threatening, biventricular failure who are not eligible for cardiac transplant will be enrolled in the Primary Arm of the study and followed for up to six months post-TAH-t implant. Safety will be evaluated by reviewing the adverse events that are experienced by the enrolled subjects and comparing them to previous experience of TAH-t patients who were waiting for a heart transplant. Since approximately 74% of patients with this condition would not be expected to live beyond six months, the benefit of the TAH-t for DT will be confirmed based on survival to six months without experiencing permanent disabling stroke-related deficits. After the six month follow-up visit, patients will continue to be followed under the study for up to five (5) years postTAH-t implant \[every six months for up to two years while supported with the TAH-t implant and then annually for another three years\]. Up to an additional 19 patients may be enrolled in the Secondary Arm of the study to further characterize the use of the TAH-t for DT in a broader patient population. Follow-up would be the same for patients enrolled in both arms of the study.

Conditions

  • Life-threatening
  • Biventricular Heart Failure
  • Ineligible for Cardiac Transplant

Interventions

  • 70cc TAH-t for Destination TherapyDevice

    Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Probable BenefitTime frame: Six Months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Banner University Medical Center Phoenix

    Phoenix, Arizona · Recruiting

  • Banner University Medical Center

    Tucson, Arizona · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.